Bamlanivimab/etesevimab

Bamlanivimab/etesevimab is a combination of two monoclonal antibodies used for the treatment of mild to moderate COVID-19 in adults and pediatric patients. This combination is administered via intravenous infusion and is specifically designed for patients who are at high risk of progressing to severe COVID-19 and/or hospitalization.

Mechanism of Action

Bamlanivimab and etesevimab are monoclonal antibodies that are specifically directed against the spike protein of SARS-CoV-2, designed to block the virus' attachment and entry into human cells. Bamlanivimab binds to the SARS-CoV-2 spike protein and blocks the virus's attachment to the human ACE2 receptor. Etesevimab binds to a different, non-overlapping epitope, providing an additional mechanism of action.

Clinical Use

The combination of bamlanivimab and etesevimab has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progressing to severe COVID-19 and/or hospitalization.

Side Effects

The most common side effects of bamlanivimab and etesevimab include nausea, dizziness, and pruritus (itching). Serious side effects can include allergic reactions, such as anaphylaxis, and severe hypersensitivity reactions.

See Also

• COVID-19 treatment
• Monoclonal antibodies
• SARS-CoV-2